Milestone Pharmaceuticals Gross Profit

The latest gross profit for MIST is $640K as of June 2026. That compares with $-28K in the prior-year period — up 2385.7% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Milestone Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, MIST's gross profit moved from $-28K to $640K — a 2385.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Milestone Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, MIST currently prints $640K for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Milestone Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $640K for MIST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting MIST's gross profit ($640K), review year-over-year change from $-28K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.